Diabetic foot disease

Endocrine Practice

Volumn 12, Issue 5, 2006, Pages 583-592

  Younes, Nidal A ^a   Ahmad, Azmi T ^a  

^a UNIVERSITY OF JORDAN   (Jordan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BECAPLERMIN; CEFOTETAN; CEFOXITIN; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; GAMMA UROGASTRONE; LEVOFLOXACIN; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN;

ANTIBIOTIC THERAPY; BONE INFECTION; BONE MALFORMATION; DEBRIDEMENT; DIABETIC FOOT; DIABETIC NEUROPATHY; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; FOOT MALFORMATION; HUMAN; HYPERGLYCEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; BIOLOGICAL MODEL; CORONARY ARTERY DISEASE; RADIOGRAPHY; SKIN DISEASE; SOFT TISSUE INFECTION;

CORONARY DISEASE; DIABETIC FOOT; FOOT DEFORMITIES; HUMANS; HYPERGLYCEMIA; MODELS, BIOLOGICAL; SKIN DISEASES; SOFT TISSUE INFECTIONS;

EID: 33947422144     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.12.5.583     Document Type: Review

References (96)

1. Reiber GE, Lipsky BA, Gibbons GW. The burden of diabetic foot ulcers. Am J Surg. 1998;176(2A Suppl):5S-10S.
2. Frykberg RG. Diabetic foot ulcers: current concepts. J Foot Ankle Surg. 1998;37:440-446.
3. American Diabetes Association. Consensus Development Conference on Diabetic Foot Wound Care: 7-8 April 1999, Boston, Massachusetts. Diabetes Care. 1999;22:1354-1360.
4. Currie CJ, Morgan CL, Peters JR. The epidemiology and cost of inpatient care for peripheral vascular disease, infection, neuropathy, and ulceration in diabetes. Diabetes Care. 1998;21:42-48.
5. Boulton AJM. Foot problems in patients with diabetes mellitus. In: Pickup JC, Williams G, eds. Textbook of Diabetes. Vol 2. Oxford, UK: Blackwell Science, 1997: 58.
6. Ramsey SD, Newton K, Blough D, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999;22:382-387.
7. Habershaw G, Chzran J. Biomechanical considerations of the diabetic foot. In: Kozak GP, Campbell DR, Frykberg RG, Habershaw GM, eds. Management of Diabetic Foot Problems. 2nd ed. Philadelphia, PA: WB Saunders, 1995: 53-65.
8. Hutton W, Stokes I. The mechanics of the foot. In: Klenerman L, ed. The Foot and Its Disorders. Oxford, England: Blackwell Scientific, 1991: 11-25.
9. Sumpio BE. Foot ulcers. N Engl J Med. 2000;343:787-793.
10. American Diabetes Association. Preventive foot care in patients with diabetes. Diabetes Care. 1999;22(Suppl 1): S54-S55.
11. Willrich A, Angirasa AK, Sage RA. Percutaneous tendo Achillis lengthening to promote healing of diabetic plantar foot ulceration. J Am Podiatr Med Assoc. 2005;95:281-284.
12. van Schie CH, Whalley A, Armstrong DG, Vileikyte L, Boulton AJ. The effect of silicone injections in the diabetic foot on peak plantar pressure and plantar tissue thickness: a 2-year follow-up. Arch Phys Med Rehabil. 2002;83: 919-923.
13. Nawoczenski DA, Birke JA, Coleman WC. Effect of rocker sole design on plantar forefoot pressures. J Am Podiatr Med Assoc. 1988;78:455-460.
14. Rathur HM, Boulton AJ. Pathogenesis of foot ulcers and the need for offloading. Horm Metab Res. 2005;37(Suppl 1):61-68.
15. Wu SC, Crews RT, Armstrong DG. The pivotal role of offloading in the management of neuropathic foot ulceration. Curr Diab Rep. 2005;5:423-429.
16. Williams PL, Bannister LH, Berry MM, et al, ed. Gray's Anatomy of the Human Body. 38th ed. London, UK: Churchill Livingstone, 1995.
17. Aitken JT, Causey G, Joseph J, Young JZ. A Manual of Human Anatomy. Vol 3. The Upper and Lower Limbs. 3rd ed. London, UK: Churchill Livingstone, 1976: 188-192.
18. Maharaj D, Bahadursingh S, Shah D, Chang BB, Darling RC III. Sepsis and the scalpel: anatomic compartments and the diabetic foot. Vasc Endovascular Surg. 2005;39:421-423.
19. Boyko EJ, Ahroni JH, Stensel V, Forsberg RC, Davignon DR, Smith DG. A prospective study of risk factors for diabetic foot ulcer: the Seattle Diabetic Foot Study. Diabetes Care. 1999;22:1036-1042.
20. Frykberg RG. Diabetic foot ulcers: pathogenesis and management. Am Fam Physician. 2002;66:1655-1662.
21. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study [erratum in Neurology. 1993;43:2345]. Neurology. 1993;43:817-824.
22. Kamei N, Yamane K, Nakanishi S, et al. Effectiveness of Semmes-Weinstein monofilament examination for diabetic peripheral neuropathy screening. J Diabetes Complications. 2005;19:47-53.
23. Cavanagh P, Young M, Adams J, et al. Correlates of structure and function in neuropathic diabetic feet [abstract]. Diabetologia. 1991;34(Suppl 2):A39.
24. Boulton A. Peripheral neuropathy and the diabetic foot. Foot. 1992;2:67-72.
25. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation. 1997;96:44-49.
26. Al-Delaimy WK, Merchant AT, Rimm EB, Willett WC, Stampfer MJ, Hu FB. Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men. Am J Med. 2004;116:236-240.
27. Elhadd TA, Robb R, Jung RT, Stonebridge PA, Belch JJ. Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic. Pract Diabetes Int. 1999;16:163-166.
28. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.
29. Dolan NC, Liu K, Criqui MH, et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care. 2002;25:113-120.
30. McDaniel MD, Cronenwett JL. Basic data related to the natural history of intermittent claudication. Ann Vasc Surg. 1989;3:273-277.
31. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J Am Coll Cardiol. 2006;47:921-929.
32. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286: 1599-1606.
33. Criqui MH, Fronek A, Klauber MR, Barrett-Connor E, Gabriel S. The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation. 1985;71:516-522.
34. Auerbach EG, Martin ET. Magnetic resonance imaging of the peripheral vasculature. Am Heart J. 2004;148:755-763.
35. Olin JW, Kaufman JA, Bluemke DA, et al (American Heart Association). Atherosclerotic Vascular Disease Conference: Writing Group IV; imaging. Circulation. 2004;109:2626-2633.
36. Macfarlane RM, Jeffcoate WJ. Factors contributing to the presentation of diabetic foot ulcers. Diabet Med. 1997;14:867-870.
37. Dinh TL, Veves A. A review of the mechanisms implicated in the pathogenesis of the diabetic foot. Int J Low Extrem Wounds. 2005;4:154-159.
38. Zimny S, Schatz H, Pfohl M. The role of limited joint mobility in diabetic patients with an at-risk foot. Diabetes Care. 2004;27:942-946.
39. Lavery LA, Armstrong DG, Boulton AJ (Diabetex Research Group). Ankle equinus deformity and its relationship to high plantar pressure in a large population with diabetes mellitus. J Am Podiatr Med Assoc. 2002;92:479-482.
40. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
41. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [erratum in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
42. Wagenknecht LE, D'Agostino RB Jr, Haffner SM, Savage PJ, Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 1998;21:1812-1818.
43. Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechomias C, Smith H. Infection and diabetes: the case for glucose control. Am J Med. 1982;72:439-450.
44. Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care. 1992;15: 256-260.
45. McMurry JF Jr. Wound healing with diabetes mellitus: better glucose control for better wound healing in diabetes. Surg Clin North Am. 1984;64:769-778.
46. Hempel A, Maasch C, Heintze U, et al. High glucose concentrations increase endothelial cell permeability via activation of protein kinase C alpha. Circ Res. 1997;81: 363-371.
47. Catrina SB, Okamoto K, Pereira T, Brismar K, Poellinger L. Hyperglycemia regulates hypoxia-inducible factor-1 alpha protein stability and function. Diabetes. 2004;53:3226-3232.
48. Mowat A, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med. 1971;284:621-627.
49. Molenaar DM, Palumbo PJ, Wilson WR, Ritts RE Jr. Leukocyte chemotaxis in diabetic patients and their nondiabetic first degree relatives. Diabetes. 1976;25(2 Suppl): 880-883.
50. MacCuish AC, Urbaniak SJ, Campbell CJ, Duncan LJ, Irvine WJ. Phytohemagglutinin transformation and circulating lymphocyte subpopulations in insulin-dependent diabetic patients. Diabetes. 1974;23:708-712.
51. Casey JI, Heeter BJ, Klyshevich KA. Impaired responses of lymphocytes of diabetic subjects to antigen of Staphylococcus aureus. J Infect Dis. 1977;136:495-501.
52. Goodson WH III, Hung TK. Studies of wound healing in experimental diabetes mellitus. J Surg Res. 1977;22:221-227.
53. Mann GV, Newton P. The membrane transport of ascorbic acid. Ann N Y Acad Sci. 1975;258:243-252.
54. Thomson FJ, Veves A, Ashe H, et al. A team approach to diabetic foot care - the Manchester experience. Foot. 1991;2:75-82.
55. Apelqvist J. Wound healing in diabetes: outcome and costs. Clin Podiatr Med Surg. 1998;15:21-39.
56. Jabbour SA. Cutaneous manifestations of endocrine disorders: a guide for dermatologists. Am J Clin Dermatol. 2003;4:315-331.
57. Ngo BT, Hayes KD, DiMiao DJ, Srinivasan SK, Huerter CJ, Rendell MS. Manifestations of cutaneous diabetic microangiopathy. Am J Clin Dermatol. 2005;6: 225-237.
58. Rogers C. Necrobiosis lipoidica diabeticorum. Dermatol Nurs. 2005;17:301, 307.
59. Zgonis T, Roukis TS. A systematic approach to diabetic foot infections. Adv Ther. 2005;22:244-262.
60. Ansari MA, Shukla VK. Foot infections. Int J Low Extrem Wounds. 2005;4:74-87.
61. Harmonson JK, Tobar MY, Harkless LB. Necrotizing fasciitis. Clin Podiatr Med Surg. 1996;13:635-646.
62. Younes NA, Albsoul AM, Awad H. Diabetic heel ulcers: a major risk factor for lower extremity amputation. Ostomy Wound Manage. 2004;50:50-60.
63. Jeffcoate WJ, Harding KG. Diabetic foot ulcers. Lancet. 2003;361:1545-1551.
64. Younes NA, Albsoul AM. The DEPA scoring system and its correlation with the healing rate of diabetic foot ulcers. J Foot Ankle Surg. 2004;43:209-213.
65. Kaushik R, Sree BS, Attri AK. Spontaneous auto-amputation of the foot in a case of diabetes, atherosclerosis and gangrene. J Indian Med Assoc. 2002;100:573-574.
66. Gibbons GW, Habershaw GM. Diabetic foot infections: anatomy and surgery. Infect Dis Clin North Am. 1995;9:131-142.
67. Newman LG, Waller J, Palestro CJ, et al. Unsuspected osteomyelitis in diabetic foot ulcers: diagnosis and monitoring by leukocyte scanning with indium In 111 oxyquinoline. JAMA. 1991;266:1246-1251.
68. Lipsky BA. Osteomyelitis of the foot in diabetic patients. Clin Infect Dis. 1997;25:1318-1326.
69. LeFrock JL, Joseph WS. Bone and soft-tissue infections of the lower extremity in diabetics. Clin Podiatr Med Surg. 1995;12:87-103.
70. Berendt AR, Lipsky B. Is this bone infected or not? Differentiating neuro-osteoarthropathy from osteomyelitis in the diabetic foot. Curr Diab Rep. 2004;4:424-429.
71. Keenan AM, Tindel NL, Alavi A. Diagnosis of pedal osteomyelitis in diabetic patients using current scintigraphic techniques. Arch Intern Med. 1989;149:2262-2266.
72. Snyder RJ, Cohen MM, Sun C, Livingston J. Osteomyelitis in the diabetic patient: diagnosis and treatment. Part 1: Overview, diagnosis, and microbiology. Ostomy Wound Manage. 2001;47:18-22, 25-30.
73. Sammak B, Abd El Bagi M, Al Shahed M, et al. Osteomyelitis: a review of currently used imaging techniques. Eur Radiol. 1999;9:894-900.
74. Khatri G, Wagner DK, Sohnle PG. Effect of bone biopsy in guiding antimicrobial therapy for osteomyelitis complicating open wounds. Am J Med Sci. 2001;321:367-371.
75. Trepman E, Nihal A, Pinzur MS. Current topics review: Charcot neuroarthropathy of the foot and ankle. Foot Ankle Int. 2005;26:46-63.
76. Sanders LJ. The Charcot foot: historical perspective 1827-2003. Diabetes Metab Res Rev. 2004;20(Suppl 1): S4-S8.
77. Scartozzi G, Kanat IO. Diabetic neuroarthropathy of the foot and ankle. J Am Podiatr Med Assoc. 1990;80:298-303.
78. Lee L, Blume PA, Sumpio B. Charcot joint disease in diabetes mellitus. Ann Vasc Surg. 2003;17:571-580.
79. Leichter SB, Allweiss P, Harley J, et al. Clinical characteristics of diabetic patients with serious pedal infections. Metabolism. 1988;37(2 Suppl 1):22-24.
80. Eneroth M, Apelqvist J, Stenstrom A. Clinical characteristics and outcome in 223 diabetic patients with deep foot infections. Foot Ankle Int. 1997;18:716-722.
81. Dargis V, Pantelejeva O, Jonushaite A, Vileikyte L, Boulton AJ. Benefits of a multidisciplinary approach in the management of recurrent diabetic foot ulceration in Lithuania: a prospective study. Diabetes Care. 1999;22: 1428-1431.
82. Joseph WS. Treatment of lower extremity infections in diabetics. J Am Podiatr Med Assoc. 1992;82:361-370.
83. Joseph WS. Treatment of lower extremity infections in diabetics. Drugs. 1991;42:984-996.
84. Tunis SR, Bass EB, Steinberg EP. The use of angioplasty, bypass surgery, and amputation in the management of peripheral vascular disease. N Engl J Med. 1991;325:556-562.
85. Graff MK, Bryant J, Beinlich N. Preventing heel breakdown. Orthop Nurs. 2000;19:63-69.
86. Smith RJ. Saving the diabetic foot. J Natl Med Assoc. 2000;92:405-410.
87. Temple ME, Nahata MC. Pharmacotherapy of lower limb diabetic ulcers. J Am Geriatr Soc. 2000;48:822-828.
88. Shea KW. Antimicrobial therapy for diabetic foot infections: a practical approach. Postgrad Med J. 1999;106:85-94.
89. Snyder RJ, Lanier KK. Offloading difficult wounds and conditions in diabetic patient. Ostomy Wound Manage. 2002;48:22-28, 30, 32-35.
90. Galiano RD, Tepper OM, Pelo CR, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. 2004;164:1935-1947.
91. Hogge J, Krasner D, Nguyen H, Harkless LB, Armstrong DG. The potential benefits of advanced therapeutic modalities in the treatment of diabetic foot wounds. J Am Podiatr Med Assoc. 2000;90:57-65.
92. Muthukumarasamy MG, Sivakumar G, Manoharan G. Topical phenytoin in diabetic foot ulcers. Diabetes Care. 1991;14:909-911.
93. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor-BB (becaplermin) in patients with chronic neuropathic diabetic ulcers: a phase III randomized placebo-controlled double-blind study. Diabetes Care. 1998;21:822-827.
94. Tsang MW, Wong WK, Hung CS, et al. Human epider mal growth factor enhances healing of diabetic foot ulcers. Diabetes Care. 2003;26:1856-1861.
95. Veves A, Falanga V, Armstrong DG, Sabolinski ML (Apligraf Diabetic Foot Ulcer Study). Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24:290-295.
96. Nwomeh BC, Yager DR, Cohen IK. Physiology of the chronic wound. Clin Plast Surg. 1998;25:341-356.